Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 75.44% is 14% above its 5-year average of 65.94%, near the high end of its 5-year range (48.98%–80.68%).
2.08% above its 12-month average of 73.90%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 71.23%.
GROSS MARGIN
75.44%
GROSS MARGIN AVG TTM
73.90%
GROSS MARGIN AVG 3Y
64.99%
GROSS MARGIN AVG 5Y
65.94%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.08%
CURRENT VS 3Y AVG
+16.07%
CURRENT VS 5Y AVG
+14.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
38.44%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
+96.25%
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.42B
Gross Margin
75.44%
TTM Avg
73.90%
3Y Avg
64.99%
5Y Avg
65.94%
Market Cap
$4.38B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.44B
Gross Margin
83.86%
TTM Avg
80.36%
3Y Avg
82.01%
5Y Avg
82.83%
Market Cap
$4.35B
Gross Margin
80.08%
TTM Avg
75.94%
3Y Avg
72.82%
5Y Avg
72.82%
Market Cap
$4.62B
Gross Margin
71.27%
TTM Avg
60.67%
3Y Avg
48.49%
5Y Avg
48.49%
Market Cap
$4.64B
Gross Margin
18.17%
TTM Avg
19.16%
3Y Avg
20.78%
5Y Avg
21.38%
Market Cap
$4.69B
Gross Margin
33.56%
TTM Avg
32.27%
3Y Avg
30.18%
5Y Avg
31.09%
Market Cap
$4.12B
Gross Margin
61.64%
TTM Avg
80.82%
3Y Avg
86.99%
5Y Avg
87.36%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.42B | 75.44% | 73.90% | 64.99% | 65.94% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.38B | 0.00% | 0.00% | 0.00% | 0.00% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | 83.86% | 80.36% | 82.01% | 82.83% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.35B | 80.08% | 75.94% | 72.82% | 72.82% |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 71.27% | 60.67% | 48.49% | 48.49% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 18.17% | 19.16% | 20.78% | 21.38% |
| LivaNova PLC (LIVN)vs › | $4.16B | 68.18% | 68.59% | 68.31% | 67.52% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 33.56% | 32.27% | 30.18% | 31.09% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.12B | 61.64% | 80.82% | 86.99% | 87.36% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.74B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
75.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 71.23% |
| 2026-03-31 | 73.60% |
| 2025-12-31 | 74.58% |
| 2025-09-30 | 80.68% |
| 2025-06-30 | 69.43% |
| 2025-03-31 | 67.62% |
| 2024-12-31 | 61.98% |
| 2024-09-30 | 64.11% |
| 2024-06-30 | 55.27% |
| 2024-03-31 | 56.89% |
| 2023-12-31 | 57.16% |
| 2023-09-30 | 48.98% |
| 2023-06-30 | 63.39% |
| 2023-03-31 | 50.38% |
| 2022-12-31 | 69.95% |
| 2022-09-30 | 68.83% |
| 2022-06-30 | 69.72% |
| 2022-03-31 | 65.84% |
| 2021-12-31 | 62.15% |
| 2021-09-30 | 64.05% |
| 2021-06-30 | 72.04% |
| 2021-03-31 | 74.01% |
| 2020-12-31 | 79.39% |
| 2020-09-30 | 76.98% |
| 2020-06-30 | 76.60% |
| 2020-03-31 | 74.45% |
| 2019-12-31 | 75.42% |
| 2019-09-30 | 78.51% |
| 2019-06-30 | 74.10% |
| 2019-03-31 | 60.62% |
| 2018-12-31 | 69.32% |
| 2018-09-30 | 68.82% |
| 2018-06-30 | 56.40% |
| 2018-03-31 | 58.94% |
